SK plasma Co., a subsidiary of South Korea's SK discovery Co., plans to build a plant to produce blood products in an investment worth 300 billion won ($227 million) in Indonesia as it aims to generate more than 300 billion won in annual sales after obtaining exclusive sales rights in the country. SK plasma is responsible for the business of therapeutic blood products made from human blood.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Yoo
Contact Yoo, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack